A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RECORD-1
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2014 Pooled analysis assessing the correlation between efficacy and incidence of stomatitis presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Feb 2014 Results from an indirect comparison of everolimus and axitinib presented at the 2014 Genitourinary Cancers Symposium.
    • 03 Feb 2011 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top